Folotyn
Showing 1 - 25 of 26
Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)
Not yet recruiting
- Peripheral T Cell Lymphoma
- Belinostat Injection
- +3 more
-
Harlingen, TexasValley Cancer Associates
Oct 16, 2023
Peripheral T-Cell Lymphoma (PTCL) Trial in United States (Pralatrexate Injection)
Completed
- Peripheral T-Cell Lymphoma (PTCL)
- Pralatrexate Injection
-
Rochester, Minnesota
- +3 more
Jul 23, 2021
Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)
Recruiting
- Lymphoma, T-Cell
- Durvalumab
- +3 more
-
Charlottesville, VirginiaUniversity of Virginia
Mar 16, 2022
Lymphoma Trial in New York (pralatrexate)
Completed
- Lymphoma
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Aug 20, 2021
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Lymphoma, B-Cell Trial in United States (Pralatrexate, Vitamin B12, Folic Acid)
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma Trial in Duarte, Wichita, Seattle (Folotyn and
Completed
- Relapsed Peripheral T-Cell Lymphoma
- Refractory Peripheral T-Cell Lymphoma
- Folotyn and Leucovorin
- +2 more
-
Duarte, California
- +2 more
Nov 18, 2019
Lymphoid Malignancies, Multiple Myeloma, Lymphoma Trial in Boston, New York (Pralatrexate, Romidepsin)
Unknown status
- Lymphoid Malignancies
- +4 more
-
Boston, Massachusetts
- +1 more
Feb 6, 2020
Peripheral T-cell Lymphoma Trial in Worldwide (Pralatrexate Injection)
Terminated
- Peripheral T-cell Lymphoma
- Pralatrexate Injection
-
Novi, Michigan
- +54 more
Nov 18, 2021
Cutaneous T-cell Lymphoma Trial in United States (Vitamin B12, Folic Acid, Pralatrexate)
Completed
- Cutaneous T-cell Lymphoma
- Vitamin B12
- +2 more
-
Duarte, California
- +9 more
Jan 2, 2020
Breast Cancer, Breast Tumors, Tumors, Breast Trial in Worldwide (Pralatrexate Injection, Vitamin B12, Folic Acid)
Completed
- Breast Cancer
- +4 more
- Pralatrexate Injection
- +2 more
-
Portland, Oregon
- +13 more
Jan 2, 2020
NSCLC Trial in Worldwide (Pralatrexate, Erlotinib, Vitamin B12)
Completed
- Non-small Cell Lung Cancer
- Pralatrexate
- +3 more
-
Bakersfield, California
- +46 more
Feb 8, 2021
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Tumor Trial in Worldwide (Pralatrexate Injection, Vitamin B12, Folic Acid)
Completed
- Carcinoma, Transitional Cell
- +2 more
- Pralatrexate Injection
- +2 more
-
Tucson, Arizona
- +18 more
Dec 10, 2019
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma Trial in United States
Completed
- Relapsed or Refractory Lymphoproliferative Malignancies
- +4 more
- Pralatrexate Injection
- +3 more
-
Los Angeles, California
- +14 more
Dec 27, 2019
Peripheral T-cell Lymphoma Trial in Worldwide (Pralatrexate Injection)
Completed
- Peripheral T-cell Lymphoma
- Pralatrexate Injection
-
Duarte, California
- +31 more
Dec 9, 2019
Solid Tumor Trial in Omaha (drug, other, genetic)
Completed
- Unspecified Adult Solid Tumor, Protocol Specific
- pralatrexate
- +9 more
-
Omaha, NebraskaUNMC Eppley Cancer Center at the University of Nebraska Medical
Jul 13, 2018
Adult T-cell Leukemia-Lymphoma Trial in Worldwide (KW-0761, Pralatrexate, gemcitabine plus oxaliplatin)
Completed
- Adult T-cell Leukemia-Lymphoma
- KW-0761
- +3 more
-
Los Angeles, California
- +19 more
Aug 21, 2018
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma Trial in United States (drug,
Completed
- Anaplastic Large Cell Lymphoma
- +3 more
- prednisone
- +12 more
-
Scottsdale, Arizona
- +8 more
May 23, 2018
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma Trial in Buffalo,
Completed
- Adenocarcinoma of the Gastroesophageal Junction
- +16 more
- Laboratory Biomarker Analysis
- +2 more
-
Buffalo, New York
- +1 more
Nov 14, 2017
Peripheral T Cell Lymphoma, Progression, Disease Trial in Taipei (Pralatrexate)
Unknown status
- Peripheral T Cell Lymphoma
- Progression, Disease
-
Taipei, TaiwanNtional Taiwan University Hospital
May 10, 2017
Advanced Cancers, Solid Tumors Trial in Houston (Erlotinib, Pralatrexate)
Completed
- Advanced Cancers
- Solid Tumors
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jul 1, 2016